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interestAbstract Heterocyclic compounds containing pyrazolines were reported to possess signiﬁcant
biological activity. Synthesis of 2-(x-chloroacetonyl)-3-p-ﬂuorophenyl-6-bromoquinazoline-4(3H)-
ones (2), 2-(x-hydrazinoacetonyl)-3-p-ﬂuorophenyl-6-bromoquinazoline-4(3H)-ones (3) and
10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azo-
methine-2-pyrazolidene]-50-(substitutedphenyl)-D2-pyrazolines (4a–j) have beendescribed. Someof the
new compounds were tested against bacteria (Gram –ve and Gram+ve) and fungi.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.
598 K.G. Desai et al.1. Introduction
The increasing environmental consciousness throughout the
world has put a pressing need to develop an alternate synthesis
approach for biologically and synthetically important com-
pounds. The present day industrialization has led to immense
environment deterioration. One of the advances in the ﬁeld of
green chemistry (Xie et al., 1999; Desai and Desai, 2006a,b;
Desai et al., 2006a,b) where substantial progress has been
made is microwave-assisted synthesis (Verma, 1999; Desai
and Desai, 2006b,c, 2007).
The chemistry and pharmacology of quinazolinone have
been of great interest to medicinal chemistry because quinaz-
olinone derivatives possessed various biological activities, such
as antibacterial (Ghorab and Abdel-Hamide, 1995; Reddy
et al., 1999), CVS (Kumar et al., 1998) and anticonvulsant
(Wolf et al., 1990). Several pyrazolines are of great
importance as antimicrobial agents (Kumar and Sinha, 1990;
Srivastava and Srivastava, 1999).
Compounds bearing the quinazolinone moiety are endowed
with various types of biological activities (Amine, 1998; Holla
et al., 1998; Kumar et al., 1985) especially anti-inﬂammatory
activity (Sarvanan et al., 1998; Khilil et al., 1994; Bhalla
et al., 1993). It is also reported that substitution of halo group
at 6-position in this nucleus enhances its anti-inﬂammatory
action. A large number of pyrazolines are reported to possess
potent antifungal and antibacterial activity (Kym et al., 1990;
Udupi et al.,1998a,b). This prompted us to synthesize a newer
series of quinazolinone derivatives by incorporating the pyraz-
oline moiety at 2nd position of the quinazolinone nucleus. We
report herein the synthesis of 2-(x-chloroacetonyl)-3-p-ﬂuoro-
phenyl-6-bromoquinazoline-4(3H)-ones (2), 2-(x-hydrazino
acetonyl)-3-p-ﬂuorophenyl-6-bromoquinazoline-4(3H)-ones
(3) and 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-
2-acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(substituted phenyl)-D2-pyrazolines (4a–j).
This starting compound 2-methyl-3-p-ﬂuorophenyl-6-bromo-
quinazoline-4(3H)-ones (1) was prepared according to the
reported method (Mishra et al., 1997).2. Results and discussion
Conventional methodology sometimes has lower yields than
microwave protocols. Microwave irradiation facilitates theTable 1 Comparative study in terms of yield and reaction period f
Entry Substituents R Microwave method
Time (min) Power (W) C
t
4a H 10.0 400 1
4b 40 0-N(CH3)2 9.0 500 1
4c 40 0-OH 9.5 450 1
4d 40 0-OCH3 9.5 450 1
4e 30 0-OC6H5 9.0 500 1
4f 30 0,40 0,50 0-(OCH3)3 10.0 400 1
4g 30 0-OCH3-40 0-OH 9.5 450 1
4h 20 0-Cl 10.0 400 1
4i 40 0-Cl 10.5 350 1
4j 40 0-NO2 10.0 400 1
a Yield of isolated products.polarization of themolecule under irradiation causing rapid reac-
tion to occur. All the compounds synthesised were adequately
characterized by their elemental analysis and spectral features.2.1. Chemistry
2-(x-Chloroacetonyl)-3-p-ﬂuorophenyl-6-bromoquinazo-
line-4(3H)-one (2) was prepared by the reaction of 2-methyl-3-
p-ﬂuorophenyl-6-bromoquinazoline-4(3H)-one (1) with ClCH2
COCl in dry tetrahydrofuran by only conventional method.
2-(x-Hydrazinoacetonyl)-3-p-ﬂuorophenyl-6-bromoquinazo-
line-4(3H)-one (3) was prepared by the reaction of 2-(x-chlo-
roacetonyl)-3-p-ﬂuorophenyl-6-bromoquinazoline-4(3H)-one
(2) with NH2NH2.H2O in absolute ethanol by both conven-
tional and microwave method. 10-[3H-3-p-Fluorophenyl-
4-oxo-6-bromoquinazoline-2-acetonyl]-30-[1-o-chlorophenyl-3-
methyl-5-azomethine-2-pyrazolidene]-50-(phenyl)-D2-pyraz-
olines (4a–j) were prepared by the reaction of 2-(x-hydrazino-
acetonyl)-3-p-ﬂuorophenyl-6-bromoquinazoline-4(3H)-one (3)
with 1-(o-chlorophenyl)-3-methylpyrazolideneazomethine-5-
chalcones (Desai and Desai, 2007; Khalafalla and Hassan,
1986) in glacial acetic acid by conventional method and in
DMF by microwave method respectively. 1-(o-Chlorophenyl)-
3-methylpyrazolideneazomethine-5-chalcones was prepared by
following the method reported in the literature (Desai and
Desai, 2007; Khalafalla and Hassan, 1986).
Compound (1) on reaction with chloroacetylchloride
yielded 2-(x-chloroacetonyl)-3-p-ﬂuorophenyl-6-bromoqui-
nazoline-4(3H)-one (2). Among the signiﬁcant features of 1H
NMR data of (1), the disappearance of singlet at d 2.50
(CH3) and appearance of two singlets at d 2.30 and d 2.50
due to the chloroacetyl group conﬁrmed the structure. Fur-
thermore, compound (2) on treatment with hydrazine hydrate
gave their corresponding 2-x-hydrazinoacetonyl-3-p-ﬂuoro-
phenyl-6-haloquinazoline-4(3H)-one (3). The appearance of
bands at 3380 and 3440 cm1 for NH and NH2, respectively
in the IR spectra, and two broad signals at d 4.55 and d 5.56
in 1H NMR spectra clearly showed the presence of hydrazino
group in compound (3). Further, compound (3) on reﬂuxing
with different 1-(o-chlorophenyl)-3-methylpyrazolideneazome-
thine-
5-chalcones in the presence of glacial acetic acid yielded the
corresponding 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinaz-
oline-2-acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-or microwave and conventional techniques (compounds 4a–j).
Conventional method
onstant
emperature (C)
Yielda (%) Time (h) Yielda (%)
16 88 16.0 65
20 82 15.5 55
18 80 16.5 60
18 83 15.0 71
20 79 17.0 59
16 86 15.5 49
18 94 16.0 68
16 90 16.5 73
14 82 15.0 54
18 89 15.5 63
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R
4a R = H
4b R = 4''-N(CH3)2
4c R = 4''-OH
4d R = 4''-OCH3
4e R = 3''-OC6H5
4f R = 3'',4'',5''-(OCH3)3
4g R = 3''-OCH3-4''-OH
4h R = 2''-Cl
4i  R = 4''-Cl
4j R = 4''-NO2
CH2
OC CH2
Scheme 1
Microwave-induced and conventional heterocyclic synthesis: An antimicrobial entites of newer 5992-pyrazolidene]-50-(substituted phenyl)-D2-pyrazolines (4a–j).
A comparative study in terms of yield and reaction period is
shown in Table 1. The synthetic route of above mentioned
compounds is shown in Scheme 1.
2.2. Microwave irradiation technique
All the reactions that used microwave irradiation (MWI) were
completed within 9–10 min, whereas similar reactions under
conventional heating (oil bath) at similar temperatures (110–
120 C) gave poor yields with comparatively longer reaction
time period (Table 1), demonstrating that the effect of micro-
wave irradiation is not purely thermal. Microwave irradiation
facilitates the polarization of the molecules under irradiation
causing rapid reaction to occur. This is consistent with the
reaction mechanism, which involves a polar transition state
(Loupy et al., 2001). The effectiveness of microwave
irradiation and conventional heating for the synthesis of
compound (4a–j) has been compared (Table 1). Under
microwave irradiation conditions, the yields of (4a–j) are
high (94–79%). Whereas using conventional heating the
yields are only 49–73%.
3. Antimicrobial activity
The compounds (4a–j) were screened for their antibacterial
activity against Bacillus substilis (ATCC 6633), Staphylococcus
aureus (ATCC 6538), Escherichia coli (ATCC 8739) and Pseu-domonas aeruginosa (ATCC 1539) and antifungal activity
against Candida albicans (ATCC 10231) and Candida krusei
(G03) by ﬁlter paper disc technique (Desai and Desai,
2005a,b, 2006d,e). Standard antibacterial and antifungal drugs
Ampicillin, Amoxicillin, Penicillin and Flucanozole were also
tested under similar conditions for comparison. Results are
presented in Table 2. By visualizing the antimicrobial data it
could be observed that some of the compounds possess signif-
icant activity.
3.1. Conclusion of activity
Zone of inhibition was measured in millimetre. The antifungal
activities were compared to the standard drug ﬂucanozole
(30–35 mm) with DMF as solvent. Ampicillin (30–35 mm),
amoxicillin (23–38 mm) and penicillin (30–38 mm) were used
as standard drugs for antibacterial activity. Compounds (2),
(4a), (4f), (4h) and (4i) showed signiﬁcant antibacterial activity.
Compounds (2), (3), (4a), (4e), (4f) and (4g) showed moderate
to good antifungal activity (Table 2).
4. Experimental
4.1. General
All the melting points were determined in PMP-DM scientiﬁc
melting point apparatus and were uncorrected. The purity of
compounds was checked routinely by TLC (0.5 mm thickness)
Table 2 Antimicrobial activity data of compounds 4a–j.
Compound Antibacterial (mm) Antifungal (mm)
Gram positive (+ve) Gram negative (ve) C. a e C. k f
S. a a B. s b E. c c P. a d
ATCC 6538 ATCC 6633 ATCC 8739 ATCC 1539 ATCC 10231 G03
2 – 22 9 25 10 25
3 15 0.9 8 18 18 22
4a 9 11 22 16 – 20
4b 8 0.8 9 1.1 12 0.8
4c 13 – 16 11 17 9
4d 7 10 13 13 – 12
4e 6 17 0.9 1.8 20 –
4f 11 21 – 19 0.9 20
4g 13 1.1 0.9 – 10 17
4h 15 20 12 12 17 8
4i – 16 – 17 10 0.7
4j 9 10 12 9 7 0.8
Zone of inhibition of standard drugs (mm)
Ampicillin 30 35 30 30 – –
Amoxicillin 25 34 38 35 – –
Penicillin 30 38 32 38 – –
Flucanozole – – – – 30 35
a S. a – Staphylococcus aureus.
bB. s – Bacills substilis.
cE. c – Escherchia coli.
d P. a – Pseudomonas aeruginosa.
e C. a – Candida albicans.
f C. k – Candida krusei.
600 K.G. Desai et al.using silica gel-G coated Al plates (Merck) and spots were
visualized by exposing the dry plates in iodine vapours. The
IR spectra (tmax in cm
1) were recorded on a shimadzu FT-
IR 8300 spectrophotometer using KBr or Nujol technique,
UV spectra (kmax in nm) were recorded on a shimadzu UV –
160 A (200–400 nm) on using DMF as solvent, 1H NMR spec-
tra on a Bruker WM 400FT MHz NMR instrument using
CDCl3 or DMSO-d6 as solvent and TMS as internal reference
(chemical shifts in d, ppm); 13C NMR on a Varian AMX 400
(100 MHz) spectrometer as solutions in CDCl3 and Mass spec-
tra on a Jeol JMS D-300 spectrometer. The elemental analysis
(C, H, N) of compounds was performed on Carlo Erba-1108
elemental analyzer. The microwave assisted reactions are
carried out in a ‘‘QPro-M Microwave Synthesis System’’
manufactured by Questron Technologies Corporation, Missis-
sauga, Ontario L4Z 2E9 has been used (Made in Canada). In
this unit, microwaves are generated by magnetron at a
frequency of 2450 MHz having an output energy range of
100–500 W and individual sensor for temperature control
(ﬁbre optic is used as a individual sensor for temperature con-
trol). There is an attachment of reﬂux condenser with constant
stirring, avoiding the risk of high pressure development and
permitting synthesis on preparative scales.
In the present work we used a new kind of QPro-M Micro-
wave Synthesis System apparatus that is well suited for strin-
gent reaction conditions [anhydrous atmosphere, controlled
temperature (ﬁbre optic is used as an individual sensor for tem-
perature control) and attachment of reﬂux condenser with con-
stant stirring]. This high-intensity microwave generator is
equipped with magnetron. The frequency can be tuned at
2450 MHz.4.2. Synthesis
4.2.1. Synthesis of 2-methyl-3-p-ﬂuorophenyl-6-bromoquinazo
line-4(3H)-one 1
These compounds were synthesized according to the method
(Mishra et al., 1997).
4.2.2. Conventional synthesis of 2-(x-chloroacetonyl)-3-p-
ﬂuorophenyl-6-bromoquinazoline-4(3H)-ones 2
To the solution of 2-Methyl-3-p-ﬂuorophenyl-6-bromoqui-
nazoline-4(3H)-one (1) (3.33 g, 0.01 mol) in dry THF
(20 mL), a solution of ClCH2COCl (2.26 mL, 0.02 mol) in
dry THF (10 mL) was added at 0 C drop wise with con-
stant stirring for 2 h. The reaction mixtures were further stir-
red for 2–4 h at room temperature, and then excess of
solvents distilled off. The reaction mixtures were cooled
and poured onto ice-cold water. The solids that separated
in each case were ﬁltered and recrystallised from ethanol
as a white solid, mp 166 C, yield (3.14 g, 77%). IR tmax:
173 (C‚O), 1590 (C‚N), 3060 (aromatic C–H), 780 (C–
Br), 740 (C–Cl), 1111 (C–F), 2570 (CH2) cm
1; 1H NMR:
d 8.75–8.30 (m, 7H, Ar-H), 2.30 (s, 2H, CH2CO), 2.50 (s,
2H, COCH2Cl) ppm; MS: m/z 415 [M
+]; Anal. Calcd. For
C17H11O2N2Cl Br F: C, 49.81; H, 2.68; N, 6.83. Found:
C, 49.83; H, 2.70; N, 6.83%.
4.2.3. Conventional synthesis of 2-(x-hydrazinoacetonyl)-3-p-
ﬂuorophenyl-6-bromo quinazoline-4(3H)-one 3
A solution of compound (2) and NH2NH2.H2O (99%) in
absolute ethanol (15 mL) was reﬂuxed for 10–12 h in a
250 mL round bottom ﬂask. The excess solvent was then
Microwave-induced and conventional heterocyclic synthesis: An antimicrobial entites of newer 601removed by distillation under reduced pressure and the residue
was poured into ice-cold water. The products that separated
were recrystallised from ethanol as a pinkish white powder,
mp 196 C, yield (2.01 g, 61%). IR tmax: 1710 (C‚O), 1580
(C‚N), 3080 (aromatic C–H), 750 (C–Br), 1113 (C–F), 2570
(CH2), 3440 (NH2), 3380 (NH) cm
1; 1H NMR: d 8.70–8.20
(m, 7H, Ar-H), 2.35 (s, 2H, CH2CO), 5.56 (br, 1H, NH,
exchangeable), 4.55 (hump, 2H, NH2, exchangeable), 2.45 (d,
2H, CH2NH) ppm; MS: m/z 411 [M
+]; Anal. Calcd. For
C17H14O2N4BrF: C, 50.37; H, 3.45; N, 13.82. Found: C,
50.34; H, 3.47; N, 13.84%.
4.2.4. Microwave mediated synthesis of 2-(x-hydrazinoaceto
nyl)-3-p-ﬂuorophenyl-6-bromo quinazoline-4(3H)-one 3
The mixture of compound (2) and NH2NH2ÆH2O (99%) in
absolute ethanol (15 mL) was taken in round bottom ﬂask
placed in a microwave oven and irradiated for about 7–8 min
(300 W, 68 C). The excess solvent was then removed by distil-
lation under reduced pressure and the residue was poured into
ice-cold water. The products that separated were recrystallised
from ethanol as a pinkish white crystal, yield (2.03 g, 83%).
4.2.5. Conventional synthesis of 10-[3H-3-p-ﬂuorophenyl-4-oxo-
6-bromoquinazoline-2-acetonyl]-30-[1-o-chlorophenyl-3-methyl-
5-azomethine-2-pyrazolidene]-50-(phenyl)-D2-pyrazoline 4a
A solution of compound (3) (4.05 g, 0.01 mol) in glacial acetic
acid (20 mL) and 1-(o-chlorophenyl)-3-methylpyrazolidene
azomethine-5-chalcones (4.13 g, 0.01 mol) was reﬂuxed for
16 h. The excess solvent was then removed by distillation under
reduced pressure and the residue was poured into ice-cold
water. The products that separated were recrystallised from
ethanol as a dark pinkish solid, mp 230 C, yield (5.14 g, 65%).
4.2.6. Microwave mediated synthesis of 10-[3H-3-p-
ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-acetonyl]-30-[1-o-
chlorophenyl-3-methyl-5-azomethine-2-pyrazolidene]-50-
(phenyl)-D2-pyrazoline 4a
A mixture of compound (3) (4.05 g, 0.01 mol) in glacial acetic
acid (20 mL) and 1-(o-chlorophenyl)-3-methylpyrazolidenea-
zomethine-5-chalcones (4.13 g, 0.01 mol) was taken in
250 mL round bottom ﬂask placed in a microwave oven and
irradiated for about 8–10 min. The excess solvent was then
removed by distillation under reduced pressure and the residue
was poured into ice-cold water. The products that separated
were recrystallised from ethanol as a dark pinkish powder,
yield (5.15 g, 88%). Likewise other compounds (4b–j) were
prepared by treating (3) with various substituted chalcones.
5. Spectral data of 10-[3H-3-p-ﬂuoro phenyl-4-oxo-6-
bromoquinazoline-2-acetonyl]-30-[1-o-chloro phenyl-3-methyl-5-
azo methine-2-pyrazolidene]-50-(substituted phenyl)-D2-
pyrazolines (4a–j)
5.1. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(phenyl)-D2-pyrazoline 4a
Dark pinkish powder, UV kmax: 313 nm; IR tmax: 1725
(C‚O), 1590 (C‚N), 3060 (aromatic C–H), 745 (C–Cl), 770
(C–Br), 1118 (C–F), 2480 (CH2), 2480, 2960 (aliphatic C–H),
1314 (C–CH3) cm
1; 1H NMR: d 8.60–7.20 (m, 20H, Ar–H),2.40 (s, 3H, CH3 attached to pyrazolidene nucleus), 5.80 (d,
2H, 2·CH2 of pyrazoline ring), 3.95 (t, 1H, CH of pyrazoline
ring), 2.26 (s, 2H, 2·CH2–CO) ppm; 13C NMR: 115–135 (aro-
matic >C‚C<), 40 (CH3), 49 (2·CH2 of pyrazoline ring), 38
(–CH2–), 189 (>C‚O), 172 (aliphatic >C‚O), 110–140 (het-
eroaromatics >C‚N–) ppm; MS: m/z 800 [M+]; Anal. Calcd.
For C42H32O2N7ClBrF: C, 62.96; H, 3.99; N, 12.24. Found: C,
62.98; H, 3.97; N, 12.26%.
5.2. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(400-dimethylaminophenyl)-D2-pyrazoline 4b
Yellowish brown solid, mp 237 C; UV kmax: 291 nm; IR tmax:
1728 (C‚O), 1598 (C‚N), 3052 (aromatic C–H), 748 (C–Cl),
767 (C–Br), 1115 (C–F), 2479 (CH2), 2485, 2957 (aliphatic C–
H), 1318 (C–CH3), 1315 [C–N(CH3)2] cm
1; 1H NMR: d 7.00–
7.95 (m, 19H, Ar-H), 2.38 (s, 3H, CH3 attached to pyrazolid-
ene nucleus), 5.85 (d, 2H, 2·CH2 of pyrazoline ring), 3.97 (t,
1H, CH of pyrazoline ring), 2.23 (s, 2H, 2·CH2–CO), 2.9
(m, 6H, –N(CH3)2) ppm;
13C NMR: 113–133 (aromatic
>C‚C<), 42 (CH3), 50 (2·CH2 of pyrazoline ring), 40
(–CH2–), 192 (>C‚O), 170 (aliphatic >C‚O), 113–143 (het-
eroaromatics >C‚N–) ppm; MS (m/z): 852 [M+]; Anal.
Calcd. for C44H37O2N8ClBrF: C, 62.00; H, 4.34; N, 13.15.
Found: C, 62.03; H, 4.37; N, 13.12%.
5.3. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(400-hydroxyphenyl)-D2-pyrazoline 4c
Dark pink powder, mp 217 C; UV kmax: 298 nm; IR tmax:
1721 (C‚O), 1589 (C‚N), 3065 (aromatic C–H), 741
(C–Cl), 772 (C–Br), 1111 (C–F), 2484 (CH2), 2478, 2964 (ali-
phatic C–H), 1315 (C–CH3), 3572 (C–OH) cm
1; 1H NMR:
d 6.98–7.93 (m, 19H, Ar-H), 2.42 (s, 3H, CH3 attached to
pyrazolidene nucleus), 5.78 (d, 2H, 2·CH2 of pyrazoline ring),
3.89 (t, 1H, CH of pyrazoline ring), 2.36 (s, 2H, 2·CH2–CO),
3.58 (s, 1H, -OH) ppm; 13C NMR: 114–131 (aromatic
>C‚C<), 43 (CH3), 53 (2·CH2 of pyrazoline ring), 37
(–CH2–), 197 (>C‚O), 174 (aliphatic >C‚O), 112–141 (het-
eroaromatics >C‚N–) ppm; MS (m/z): 813 [M+]; Anal.
Calcd. for C42H33O2N7ClBrF: C, 61.70; H, 4.04; N, 12.00.
Found: C, 61.72; H, 4.06; N, 12.03%.
5.4. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(400-methoxyphenyl)-D2-pyrazoline 4d
Brown powder, mp 247250 C; UV kmax: 320 nm; IR tmax:
1730 (C‚O), 1578 (C‚N), 3050 (aromatic C–H), 744 (C–
Cl), 780 (C–Br), 1128 (C–F), 2475 (CH2), 2485, 2965 (aliphatic
C–H), 1317 (C–CH3), 2831 (C–OCH3) cm
1; 1H NMR: d7.20–
7.90 (m, 19H, Ar-H), 2.31 (s, 3H, CH3 attached to pyrazolid-
ene nucleus), 5.72 (d, 2H, 2·CH2 of pyrazoline ring), 3.99 (t,
1H, CH of pyrazoline ring), 2.28 (s, 2H, 2·CH2–CO), 3.89
(s, 3H, –OCH3) ppm;
13C NMR: 115–135 (aromatic
>C‚C<), 44 (CH3), 51 (2·CH2 of pyrazoline ring), 39
(–CH2–), 199 (>C‚O), 171 (aliphatic >C‚O), 35.7
(OCH3), 112–145 (heteroaromatics >C‚N–) ppm; MS (m/
z): 832 [M+]; Anal. Calcd. for C43H34O3N7ClBrF: C, 62.13;
H, 4.09; N, 11.80. Found: C, 62.10; H, 4.11; N, 11.83%.
602 K.G. Desai et al.5.5. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(300-phenoxyphenyl)-D2-pyrazoline 4e
Violet powder, mp 199 C; UV kmax: 300 nm; IR tmax: 1721
(C‚O), 1593 (C‚N), 3061 (aromatic C–H), 748 (C–Cl), 771
(C–Br), 1113 (C–F), 2473 (CH2), 2467, 2964 (aliphatic C–H),
1310 (C–CH3) cm
1; 1H NMR: d 6.85–7.65 (m, 24H, Ar-H),
2.34 (s, 3H, CH3 attached to pyrazolidene nucleus), 5.86 (d,
4H, 2·CH2 of pyrazoline ring), 3.91 (t, 1H, CH of pyrazoline
ring), 2.37 (s, 2H, 2·CH2–CO), 6.79–7.77 (m, 5H, –OC6H5)
ppm; 13C NMR: 111–132 (aromatic >C‚C<), 42 (CH3), 50
(2·CH2 of pyrazoline ring), 39 (–CH2–), 194 (>C‚O), 170 (ali-
phatic>C‚O), 115–148 (heteroaromatics>C‚N–) ppm;MS
(m/z): 890 [M+]; Anal. Calcd. for C48H36O3N7ClBrF: C, 64.53;
H, 4.03; N, 10.98. Found: C, 64.56; H, 4.06; N, 10.95% .
5.6. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(300,400,500-trimethoxyphenyl)-D2-pyrazoline 4f
Dark brown crystal, mp 202 C; UV kmax: 275 nm; IR tmax:
1725 (C‚O), 1591 (C‚N), 3062 (aromatic C–H), 743 (C–
Cl), 771 (C–Br), 1112 (C–F), 2483 (CH2), 2481, 2962 (aliphatic
C–H), 1313 (C–CH3), 2828 [C–(OCH3)3] cm
1; 1H NMR: d
6.99–7.80 (m, 17H, Ar–H), 2.45 (s, 3H, CH3 attached to
pyrazolidene nucleus), 5.89 (d, 2H, 2·CH2 of pyrazoline ring),
3.87 (t, 1H, CH of pyrazoline ring), 2.31 (s, 2H, 2·CH2- CO),
3.92 (s, 3H, –OCH3) ppm;
13C NMR: 110–135 (aromatic
>C‚C<), 37 (CH3), 50 (2·CH2 of pyrazoline ring), 38.7
(–CH2–), 189 (>C‚O), 171 (aliphatic >C‚O), 37.5
(3·OCH3), 110–140 (heteroaromatics >C‚N–) ppm; MS
(m/z): 893 [M+]; Anal. Calcd. for C45H40O5N7ClBrF: C,
60.64; H, 4.49; N, 11.00. Found: C, 60.66; H, 4.51; N, 11.04%.
5.7. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(300-methoxy-400-hydroxyphenyl)-D2-
pyrazoline 4g
Light brown powder, mp 250255 C; UV kmax: 277 nm; IR t
max: 1728 (C‚O), 1590 (C‚N), 3060 (aromatic C–H), 745 (C–
Cl), 770 (C–Br), 1118 (C–F), 2480 (CH2), 2480, 2960 (aliphatic
C–H), 1312 (C–CH3), 3566 (C–OH), 2825 (C– OCH3) cm
1;
1HNMR: d6.78–7.86 (m, 18H,Ar-H), 2.48 (s, 3H,CH3 attached
topyrazolidene nucleus), 5.79 (d, 2H, 2·CH2of pyrazoline ring),
3.82 (t, 1H, CH of pyrazoline ring), 2.27 (s, 2H, 2·CH2–CO),
3.79 (s, 3H, - OCH3), 3.50 (s, 1H, -OH) ppm;
13C NMR: 112–
134 (aromatic >C‚C<), 44 (CH3), 48 (2·CH2 of pyrazoline
ring), 35 (–CH2–), 193 (>C‚O), 169 (aliphatic >C‚O),
113–148 (heteroaromatics >C‚N–) ppm; MS (m/z): 847
[M+]; Anal. Calcd. for C43H35O4N7ClBrF: C, 60.95; H, 4.13;
N, 11.57. Found: C, 60.93; H, 4.16; N, 11.60%.
5.8. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(200-chlorophenyl)-D2-pyrazoline 4h
Yellow powder, mp 241 C; UV kmax: 335 nm; IR tmax: 1726
(C‚O), 1592 (C‚N), 3063 (aromatic C–H), 749 (C–Cl), 775
(C–Br), 1120 (C–F), 2482 (CH2), 2488, 2966 (aliphatic C–H),
1315 (C–CH3) cm
1; 1H NMR: d 6.65–7.77 (m, 17H, Ar-H),2.42 (s, 3H, CH3 attached to pyrazolidene nucleus), 5.88 (d,
2H, 2·CH2 of pyrazoline ring), 3.96 (t, 1H, CH of pyrazoline
ring), 2.22 (s, 2H, 2·CH2–CO) ppm; 13C NMR: 114–131 (aro-
matic >C‚C<), 41 (CH3), 55 (2·CH2 of pyrazoline ring), 38
(–CH2–), 188 (>C‚O), 175 (aliphatic >C‚O), 118–150 (het-
eroaromatics >C‚N–) ppm; MS (m/z): 835 [M+]; Anal.
Calcd. for C42H31O2N7Cl2BrF: C, 60.35; H, 3.71; N, 11.73.
Found: C, 60.37; H, 3.73; N, 11.74%.
5.9. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(40 0-chlorophenyl)-D2-pyrazolines 4i
Pale yellow crystalline powder, mp 250 C; UV kmax: 298 nm;
IR tmax: 1730 (C‚O), 1588 (C‚N), 3058 (aromatic C–H),
735 (C–Cl), 773 (C–Br), 1120 (C–F), 2481 (CH2), 2482, 2961
(aliphatic C–H), 1314 (C–CH3) cm
1; 1H NMR: d 6.72–7.82
(m, 17H, Ar-H), 2.44 (s, 3H, CH3 attached to pyrazolidene
nucleus), 5.90 (d, 2H, 2·CH2 of pyrazoline ring), 3.92 (t, 1H,
CH of pyrazoline ring), 2.33 (s, 2H, 2·CH2–CO) ppm; 13C
NMR: 114–134 (aromatic >C‚C<), 41 (CH3), 49 (2·CH2
of pyrazoline ring), 36 (–CH2–), 196 (>C‚O), 170 (aliphatic
>C‚O), 116–142 (heteroaromatics >C‚N–) ppm; MS (m/
z): 837 [M+]; Anal. Calcd. for C42H31O2N7Cl2BrF: C, 60.35;
H, 3.71; N, 11.73. Found: C, 60.33; H, 3.72; N, 3.72%.
5.10. 10-[3H-3-p-ﬂuorophenyl-4-oxo-6-bromoquinazoline-2-
acetonyl]-30-[1-o-chlorophenyl-3-methyl-5-azomethine-2-
pyrazolidene]-50-(40 0-nitrophenyl)-D2-pyrazoline 4j
Pink powder, mp 262 C; UV kmax: 288 nm; IR tmax: 1728
(C‚O), 1596 (C‚N), 3061 (aromatic C–H), 748 (C–Cl), 771
(C–Br), 1118 (C–F), 2481 (CH2), 2487, 2967 (aliphatic C–H),
1315 (C–CH3), 1340 (C–NO2) cm
1; 1H NMR: d 7.15–7.92
(m, 19H, Ar-H), 2.36 (s, 3H, CH3 attached to pyrazolidene
nucleus), 5.76 (d, 2H, 2·CH2 of pyrazoline ring), 3.88 (t, 1H,
CH of pyrazoline ring), 2.36 (s, 2H, 2·CH2–CO) ppm; 13C
NMR: 113–133 (aromatic >C‚C<), 43 (CH3), 50 (2·CH2
of pyrazoline ring), 37 (–CH2–), 185 (>C‚O), 172 (aliphatic
>C‚O), 114–146 (heteroaromatics >C‚N–) ppm; MS
(m/z): 847 [M+]; Anal. Calcd. for C42H31O4N8ClBrF: C,
59.60; H, 3.66; N, 13.24. Found: C, 59.61; H, 3.68; N, 13.21%.6. Conclusion
In conclusion, this new method for the synthesis of quinazoli-
nyl-D2-pyrazolines in glacial acetic acid under microwave
irradiation offers signiﬁcant improvements over existing proce-
dures and thus helps facile entry into a variety of quinazolinyl-
D2-pyrazolines of potentially high synthetic utility. Also, this
simple and reproducible technique affords various quinazoli-
nyl-D2-pyrazolines with short reaction times, excellent yields,
and without formation of undesirable by-products.
A series of quinazolinyl-D2-pyrazolines derivatives were pre-
pared and tested for their in vitro antibacterial activity against
the four strains of bacteria (gram+ve, gram–ve) and antifungal
activities against the two strains of human pathogenic fungi.
Five compounds of the obtained series showed high in vitro anti-
microbial activity. 2-(x-chloroacetonyl)-3-p-ﬂuorophenyl-6-
bromoquinazoline-4(3H)-ones (2) showed excellent activity
against B. substilis and P. aeruginosa, 10-[3H-3-p-ﬂuorophenyl-
Microwave-induced and conventional heterocyclic synthesis: An antimicrobial entites of newer 6034-oxo-6-bromoquinazoline-2-acetonyl]-30-[1-o-chlorophenyl-3-
methyl-5-azomethine-2-pyrazolidene]-50-(phenyl)-D2-pyrazoline
(4a) showed excellent activity against E. coli indicated in vitro
antibacterial activity comparable to or slightly lower than that
of Ampicillin, Amoxicillin and Penicillin. Compound (2) and
2-(x-hydrazinoacetonyl)-3-p-ﬂuorophenyl-6-bromo quinazo-
line-4(3H)-one (3) showed excellent activity against C. krusei
indicated in vitro antifungal activity comparable to or slightly
lower than that of ﬂucanozole. The substitution in the C(4) posi-
tion of the phenyl ring by methoxy, chloro and phenoxy groups
seems to be very important for antifungal effect, as well as the
presence and the position of the –CH2COCH2– group in the
connecting linker between the quinazoline and pyrazoline ring
and quinazolinyl-D2-pyrazolines derivatives seems to be very
important for anti bacterial effect.Acknowledgements
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